• EverythingALS Advances a New Clinical Research Model for ALS Trials

    Clinical Research News | The promise of AI was on full display at last week’s SCOPE event in Orlando, peppering each of hundreds of presentations focused on the future of clinical research. Analysts have projected that AI in clinical trials will represent an $8 billion business segment by 2030, generating up to $110 billion per year in value to pharma, but that will not happen unless the workflows are redesigned.

    Feb 11, 2026

  • EverythingALS Advances a New Clinical Research Model for ALS Trials

    Clinical Research News | Clinical research in amyotrophic lateral sclerosis has long been hindered by subjective endpoints, slow enrollment, and limited tools for tracking disease progression. EverythingALS, a nonprofit initiative, is addressing those barriers with a speech-based digital biomarker designed to modernize how ALS trials are conducted and evaluated.

    Feb 11, 2026

  • AI’s Promise Hinges on Redesigning Workflows

    Clinical Research News | The promise of AI was on full display at last week’s SCOPE event in Orlando, peppering each of hundreds of presentations focused on the future of clinical research. Analysts have projected that AI in clinical trials will represent an $8 billion business segment by 2030, generating up to $110 billion per year in value to pharma, but that will not happen unless the workflows are redesigned.

    Feb 10, 2026

  • SCOPE 2026: And The Winners Are…

    Clinical Research News | SCOPE 2026 kicked off in Orlando this week honoring XX groups with awards recognizing their technical innovations and creative work in service of patients and sites. The honored groups were Biogen, Proximity Health Solutions, TrialScreen, The Association of Multisite Research Corporations (AMRC), and new product awards for Biorce, ZigZag, Medidata, Innovative Trials, and Anju.

    Feb 5, 2026

  • Hope: A Tricky Concept for Trial Participants With Rare Conditions

    Clinical Research News | ORLANDO—For patients with a rare disease participating in clinical trials, hope can be a “doubled-edged sword,” potentially saving their lives but also burdening them with enormous, if unintended, hidden costs. Hope is also their “trust in us” as they desperately search for restorative treatments like chimeric antigen receptor (CAR) T-cell therapy, Jane Myles told a packed house during the opening day plenary keynote address at this week’s SCOPE event in Orlando.

    Feb 3, 2026

  • SCOPE 2026: AI in Clinical Research Poised for Boom Times

    Clinical Research News | An assortment of new product launches, funding news, and leadership appointments were announced in conjunction with this week’s SCOPE event in Orlando, which is experiencing a record-breaking attendance exceeding 4,800 people. The announcements serve as a potent reminder that artificial intelligence is having a field day in clinical research, and the common aim is right sizing the time and cost of getting medicines to market.

    Feb 3, 2026

  • SCOPE 2026: AI in Clinical Research Poised for Boom Times

    Clinical Research News | An assortment of new product launches, funding news, and leadership appointments were announced in conjunction with this week’s SCOPE event in Orlando, which is experiencing a record-breaking attendance exceeding 4,800 people. The announcements serve as a potent reminder that artificial intelligence is having a field day in clinical research, and the common aim is right sizing the time and cost of getting medicines to market.

    Feb 3, 2026

  • SCOPE 2026 Best of Show Entries

    Clinical Research News | SCOPE is kicking off this week and among all of the other events, speakers, and awards programs planned, the Best of Show awards again brings an impressive docket of new products to the SCOPE exhibit hall floor with a record-breaking 70 new products on display in Orlando.

    Feb 2, 2026

  • Follow the Money: Using AI for Clinical Enrollment, Pan-KRAS Degrader Trial, MoreBy Clinical Research Staff

    Clinical Research News | Mendra aims to employ AI to accelerate patient identification and clinical trial enrollment; PAQ Therapeutics will advance its ongoing Phase 1 development of PT0253, PAQ's KRAS G12D degrader; and more.

    Jan 28, 2026